McDermott and Bull executive Search
 

Other News

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Rhythm by 0 comments

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac […]

Continue Reading →

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

Coronary/Structural Heart by 0 comments

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.–Feb. 5, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and […]

Continue Reading →

Late-breaking data presentations showcase the safety and efficacy of Abbott’s ablation catheters to treat people with atrial fibrillation

Rhythm by 0 comments

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System’s industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE…

Continue Reading →

Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas

Neuro by 0 comments

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with large symptomatic chronic subdural hematoma(s) (cSDH).

Continue Reading →

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Coronary/Structural Heart by 0 comments

GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ — Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it is broadening the development focus…

Continue Reading →

Bristol Myers Squibb Introduces “Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care

Coronary/Structural Heart by 0 comments

Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the U.S. annually Clinician-focused educational program, developed in partnership with Johnson & Johnson, highlights care for patients at high risk of thromboembolic events such as stroke, and the emerging potential […]

Continue Reading →

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Financial by 0 comments

Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.–Feb. 3, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will […]

Continue Reading →

RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment

Coronary/Structural Heart by 0 comments

Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules,  announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™),  a […]

Continue Reading →
1 2 3 … 1,300